Microarray Synthesis and Assembly of Gene-Length Polynucleotides

ABSTRACT

There is disclosed a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there is disclosed a process for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, “on device” assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.14/701,957 filed May 1, 2015, which is a continuation of U.S. patentapplication Ser. No. 13/617,685 filed Sep. 14, 2012, now U.S. Pat. No.9,051,666, which is a continuation of U.S. patent application Ser. No.13/250,207 filed Sep. 30, 2011, now U.S. Pat. No. 9,023,601, which is acontinuation of U.S. patent application Ser. No. 12/488,662 filed Jun.22, 2009, now U.S. Pat. No. 8,058,004, which is a continuation of U.S.patent application Ser. No. 10/243,367 filed Sep. 12, 2002, now U.S.Pat. No. 7,563,600, the content of all of which applications isincorporated herein by reference in their entirety.

TECHNICAL FIELD OF THE INVENTION

The present invention provides a process for in vitro synthesis andassembly of long, gene-length polynucleotides based upon assembly ofmultiple shorter oligonucleotides synthesized in situ on a microarrayplatform. Specifically, the present invention provides a process for insitu synthesis of oligonucleotide sequence fragments on a solid phasemicroarray platform and subsequent, “on chip” assembly of largerpolynucleotides composed of a plurality of smaller oligonucleotidesequence fragments.

BACKGROUND OF THE INVENTION

In the world of microarrays, biological molecules (e.g.,oligonucleotides, polypeptides and the like) are placed onto surfaces atdefined locations for potential binding with target samples ofnucleotides or receptors. Microarrays are miniaturized arrays ofbiomolecules available or being developed on a variety of platforms.Much of the initial focus for these microarrays have been in genomicswith an emphasis of single nucleotide polymorphisms (SNPs) and genomicDNA detection/validation, functional genomics and proteomics (Wilgenbusand Lichter, J. Mol. Med. 77:761, 1999; Ashfari et al., Cancer Res.59:4759, 1999; Kurian et al., J. Pathol. 187:267, 1999; Hacia, NatureGenetics 21 suppl. 42, 1999; Hacia et al., Mol. Psychiatry 3:483, 1998;and Johnson, Curr. Biol. 26:R171, 1998).

There are, in general, three categories of microarrays (also called“biochips” and “DNA Arrays” and “Gene Chips” but this descriptive namehas been attempted to be a trademark) having oligonucleotide content.Most often, the oligonucleotide microarrays have a solid surface,usually silicon-based and most often a glass microscopic slide.Oligonucleotide microarrays are often made by different techniques,including (1) “spotting” by depositing single nucleotides for in situsynthesis or completed oligonucleotides by physical means (ink jetprinting and the like), (2) photolithographic techniques for in situoligonucleotide synthesis (see, for example, Fodor U.S. Patent '934 andthe additional patents that claim priority from this priority document,(3) electrochemical in situ synthesis based upon pH based removal ofblocking chemical functional groups (see, for example, Montgomery U.S.Pat. No. 6,092,302 the disclosure of which is incorporated by referenceherein and Southern U.S. Pat. No. 5,667,667), and (4) electric fieldattraction/repulsion of fully-formed oligonucleotides (see, for example,Hollis et al., U.S. Pat. No. 5,653,939 and its duplicate Heller U.S.Pat. No. 5,929,208). Only the first three basic techniques can formoligonucleotides in situ e.g., building each oligonucleotide,nucleotide-by-nucleotide, on the microarray surface without placing orattracting fully formed oligonucleotides.

With regard to placing fully formed oligonucleotides at specificlocations, various micro-spotting techniques using computer-controlledplotters or even ink-jet printers have been developed to spotoligonucleotides at defined locations. One technique loads glass fibershaving multiple capillaries drilled through them with differentoligonucleotides loaded into each capillary tube. Microarray chips,often simply glass microscope slides, are then stamped out much like arubber stamp on each sheet of paper of glass slide. It is also possibleto use “spotting” techniques to build oligonucleotides in situ.Essentially, this involves “spotting” relevant single nucleotides at theexact location or region on a slide (preferably a glass slide) where aparticular sequence of oligonucleotide is to be built. Therefore,irrespective of whether or not fully formed oligonucleotides or singlenucleotides are added for in situ synthesis, spotting techniques involvethe precise placement of materials at specific sites or regions usingautomated techniques.

Another technique involves a photolithography process involvingphotomasks to build oligonucleotides in situ, base-by-base, by providinga series of precise photomasks coordinated with single nucleotide baseshaving light-cleavable blocking groups. This technique is described inFodor et al., U.S. Pat. No. 5,445,934 and its various progeny patents.Essentially, this technique provides for “solid-phase chemistry,photolabile protecting groups, and photolithography . . . to achievelight-directed spatially-addressable parallel chemical synthesis.”

The electrochemistry platform (Montgomery U.S. Pat. No. 6,092,302, thedisclosure of which is incorporated by reference herein) provides amicroarray based upon a semiconductor chip platform having a pluralityof microelectrodes. This chip design uses Complimentary Metal OxideSemiconductor (CMOS) technology to create high-density arrays ofmicroelectrodes with parallel addressing for selecting and controllingindividual microelectrodes within the array. The electrodes turned onwith current flow generate electrochemical reagents (particularly acidicprotons) to alter the pH in a small “virtual flask” region or volumeadjacent to the electrode. The microarray is coated with a porous matrixfor a reaction layer material. Thickness and porosity of the material iscarefully controlled and biomolecules are synthesized within volumes ofthe porous matrix whose pH has been altered through controlled diffusionof protons generated electrochemically and whose diffusion is limited bydiffusion coefficients and the buffering capacities of solutions.However, in order to function properly, the microarray biochips usingelectrochemistry means for in situ synthesis has to alternate anodes andcathodes in the array in order to generated needed protons (acids) atthe anodes so that the protons and other acidic electrochemicallygenerated acidic reagents will cause an acid pH shift and remove ablocking group from a growing oligomer.

Gene Assembly

The preparation of arbitrary polynucleotide sequences is useful in a“postgenomic” era because it provides any desirable gene oligonucleotideor its fragment, or even whole genome material of plasmids, phages andviruses. Such polynucleotides are long, such as in excess of 1000 basesin length. In vitro synthesis of oligonucleotides (given even the bestyield conditions of phosphoramidite chemistry) would not be feasiblebecause each base addition reaction is less than 100% yield. Therefore,researchers desiring to obtain long polynucleotides of gene length orlonger had to turn to nature or gene isolation techniques to obtainpolynucleotides of such length. For the purposes of this patentapplication, the term “polynucleotide” shall be used to refer to nucleicacids (either single stranded or double stranded) that are sufficientlylong so as to be practically not feasible to make in vitro throughsingle base addition. In view of the exponential drop-off in yields fromnucleic acid synthesis chemistries, such as phosphoramidite chemistry,such polynucleotides generally have greater than 100 bases and oftengreater than 200 bases in length. It should be noted that manycommercially useful gene cDNA's often have lengths in excess of 1000bases.

Moreover, the term “oligonucleotides” or shorter term “oligos” shall beused to refer to shorter length single stranded or double strandednucleic acids capable of in vitro synthesis and generally shorter than150 bases in length. While it is theoretically possible to synthesizepolynucleotides through single base addition, the yield losses make it apractical impossibility beyond 150 bases and certainly longer than 250bases. However, knowledge of the precise structure of the geneticmaterial is often not sufficient to obtain this material from naturalsources. Mature cDNA, which is a copy of an mRNA molecule, can beobtained if the starting material contains the desired mRNA. However, itis not always known if the particular mRNA is present in a sample or theamount of the mRNA might be too low to obtain the corresponding cDNAwithout significant difficulties. Also, different levels of homology orsplice variants may interfere with obtaining one particular species ofmRNA. On the other hand many genomic materials might be not appropriateto prepare mature gene (cDNA) due to exon-intron structure of genes inmany different genomes.

In addition, there is a need in the art for polynucleotides not existingin nature to improve genomic research performance. In general, theability to obtain a polynucleotide of any desired sequence just knowingthe primary structure, for a reasonable price, in a short period oftime, will significantly move forward several fields of biomedicalresearch and clinical practice.

Assembly of long arbitrary polynucleotides from oligonucleotidessynthesized by organic synthesis and individually purified has otherproblems. The assembly can be performed using PCR or ligation methods.The synthesis and purification of many different oligonucleotides byconventional methods (even using multi-channel synthesizers) arelaborious and expensive procedures. The current price of assembledpolynucleotide on the market is about $12-25 per base pair, which can beconsiderable for assembling larger polynucleotides. Very often theamount of conventionally synthesized oligonucleotides would beexcessive. This also contributes to the cost of the final product.

Therefore, there is a need in the art to provide cost-effectivepolynucleotides by procedures that are not as cumbersome andlabor-intensive as present methods to be able to provide polynucleotidesat costs below $1 per base or 1-20 times less than current methods. Thepresent invention was made to address this need.

SUMMARY OF THE INVENTION

The present invention provides a process for the assembly ofoligonucleotides synthesized on microarrays into a polynucleotidesequence. The desired target polynucleotide sequence is dissected intopieces of overlapping oligonucleotides. In the first embodiment theseoligonucleotides are synthesized in situ, in parallel on a microarraychip in a non-cleavable form. A primer extension process assembles thetarget polynucleotides. The primer extension process uses startingprimers that are specific for the appropriate sequences. The last stepis PCR amplification of the final polynucleotide product. Preferably,the polynucleotide product is a cDNA suitable for transcription purposesand further comprising a promoter sequence for transcription.

The present invention provides a process for assembling a polynucleotidefrom a plurality of oligonucleotides comprising:

(a) synthesizing or spotting a plurality of oligonucleotide sequences ona microarray device or bead device having a solid or porous surface,wherein a first oligonucleotide is oligo 1 and a second oligonucleotideis oligo 2 and so on, wherein the plurality of oligonucleotide sequencesare attached to the solid or porous surface, and wherein the firstoligonucleotide sequence has an overlapping sequence region of fromabout 10 to about 50 bases that is the same or substantially the same asa region of a second oligonucleotide sequence, and wherein the secondoligonucleotide sequence has an overlapping region with a thirdoligonucleotide sequence and so on;

(b) forming complementary oligo 1 by extending primer 1, wherein primer1 is complementary to oligo 1;

(c) disassociating complementary oligo 1 from oligo 1 and annealingcomplementary oligo 1 to both oligo 1 and to the overlapping region ofoligo 2, wherein the annealing of complementary oligo 1 to oligo 2serves as a primer for extension for forming complementary oligo 1+2;

(d) repeating the primer extension cycles of step (c) until afull-length polynucleotide is produced; and

(e) amplifying the assembled complementary full length polynucleotide toproduce a full length polynucleotide in desired quantities.

Preferably, the solid or porous surface is in the form of a microarraydevice. Most preferably, the microarray device is a semiconductor devicehaving a plurality of electrodes for synthesizing oligonucleotides insitu using electrochemical means to couple and decouple nucleotidebases. Preferably, the primer extension reaction is conducted through asequential process of melting, annealing and then extension. Mostpreferably, the primer extension reaction is conducted in a PCRamplification device using the microarray having the plurality ofoligonucleotides bound thereto.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has an overlapping region corresponding to anext oligonucleotide sequence within the sequence and further comprisestwo flanking sequences, one at the 3′ end and the other at the 5′ end ofeach oligonucleotide, wherein each flanking sequence is from about 7 toabout 50 bases and comprising a primer region and a sequence segmenthaving a restriction enzyme cleavable site;

(b) amplifying each oligonucleotide using the primer regions of theflanking sequence to form double stranded (ds) oligonucleotides;

(c) cleaving the oligonucleotide sequences at the restriction enzymecleavable site; and

(d) assembling the cleaved oligonucleotide sequences through theoverlapping regions to form a full length polynucleotide.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the flankingsequence further comprises a binding moiety used to purify cleavedoligonucleotides from flanking sequences. Preferably, the processfurther comprises the step of labeling the flanking sequence during theamplification step (b) using primer sequences labeled with bindingmoieties. Most preferably, a binding moiety is a small molecule able tobe captured, such as biotin captured by avidin or streptavidin, orfluorescein able to be captured by an anti-fluorescein antibody.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has an overlapping region corresponding to anext oligonucleotide sequence within the sequence, and further comprisesa sequence segment having a cleavable linker moiety;

(b) cleaving the oligonucleotide sequences at the cleavable linker siteto cleave each oligonucleotide complex from the microarray or bead solidsurface to form a soluble mixture of oligonucleotides, each having anoverlapping sequence; and

(c) assembling the oligonucleotide sequences through the overlappingregions to form a full length polynucleotide.

Preferably, the cleavable linker is a chemical composition having asuccinate moiety bound to a nucleotide moiety such that cleavageproduces a 3′hydroxy nucleotide. Most preferably, the cleavable linkeris selected from the group consisting of 5′-dimethoxytrityl-thymidine-3′succinate, 4-N-benzoyl-5′-dimethoxytrityl-deoxycytidine-3′-succinate,1-N-benzoyl-5′-dimethoxytrityl-deoxyadenosine-3′-succinate,2-N-isobutyryl-5′-dimethoxytrityl-deoxyguanosine-3′-succinate, andcombinations thereof.

The present invention further provides a process for assembling apolynucleotide from a plurality of oligonucleotides comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a flanking region at an end attached to thesolid or porous surface, and a specific region designed by dissectingthe polynucleotide sequence into a plurality of overlappingoligonucleotides, wherein a first overlapping sequence on a firstoligonucleotide corresponds to a second overlapping sequence of a secondoligonucleotide, and wherein the flanking sequence comprises a sequencesegment having a restriction endonuclease (RE) recognition sequencecapable of being cleaved by a corresponding RE enzyme;

(b) hybridizing an oligonucleotide sequence complementary to theflanking region to form a double stranded sequence capable ofinteracting with the corresponding RE enzyme;

(c) digesting the plurality of oligonucleotides to cleave them from themicroarray device or beads into a solution; and

(d) assembling the oligonucleotide mixture through the overlappingregions to form a full length polynucleotide.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the process furthercomprises a final step of amplifying the polynucleotide sequence usingprimers located at both ends of the polynucleotide.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence further comprises two flanking sequences, oneat the 3′ end and the other at the 5′ end of each oligonucleotide,wherein each flanking sequence is from about 7 to about 50 bases andcomprising a primer region and a sequence segment having a restrictionenzyme cleavable site;

(b) amplifying each oligonucleotide using the primer regions of theflanking sequence to form a double stranded (ds) oligonucleotides; and

(c) cleaving the double stranded oligonucleotide sequences at therestriction enzyme cleavable site.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof. Preferably, the flankingsequence further comprises a binding moiety used to purify cleavedoligonucleotides from flanking sequences. Preferably, the processfurther comprises the step of labeling the flanking sequence during theamplification step (b) using primer sequences labeled with bindingmoieties. Most preferably, a binding moiety is a small molecule able tobe captured, such as biotin captured by avidin or streptavidin, orfluorescein able to be captured by an anti-fluorescein antibody.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a sequence segment having a cleavablelinker moiety;

(b) cleaving the oligonucleotide sequences at the cleavable linker siteto cleave each oligonucleotide sequence from the microarray or beadsolid surface to form a soluble mixture of oligonucleotides.

Preferably, the cleavable linker is a chemical composition having asuccinate moiety bound to a nucleotide moiety such that cleavageproduces a 3′hydroxy nucleotide. Most preferably, the cleavable linkeris selected from the group consisting of 5′-dimethoxytrityl-thymidine-3′succinate, 4-N-benzoyl-5′-dimethoxytrityl-deoxycytidine-3′-succinate,1-N-benzoyl-5′-dimethoxytrityl-deoxyadenosine-3′-succinate,2-N-isobutyryl-5′-dimethoxytrityl-deoxyguanosine-3′-succinate, andcombinations thereof.

The present invention further provides a process for creating a mixtureof oligonucleotide sequences in solution comprising:

(a) synthesizing in situ or spotting a plurality of oligonucleotidesequences on a microarray device or bead device each having a solid orporous surface, wherein the plurality of oligonucleotide sequences areattached to the solid or porous surface, and wherein eacholigonucleotide sequence has a flanking region at an end attached to thesolid or porous surface, and a specific region, wherein the flankingsequence comprises a sequence segment having a restriction endonuclease(RE) recognition sequence capable of being cleaved by a corresponding REenzyme;

(b) hybridizing an oligonucleotide sequence complementary to theflanking region to form a double stranded sequence capable ofinteracting with the corresponding RE enzyme;

(c) digesting the plurality of oligonucleotides to cleave them from themicroarray device or beads into a solution.

Preferably, the flanking sequence is from about 10 to about 20 bases inlength. Preferably, the restriction enzyme cleavable site is a class IIendonuclease restriction site sequence capable of being cleaved by itscorresponding class II restriction endonuclease enzyme. Most preferably,the restriction endonuclease class II site corresponds to restrictionsites for a restriction endonuclease class II enzyme selected from thegroup consisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I,Bts I, Fok I, and combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C show schematics of gene assembly on a microarray devicesurface or porous matrix. In FIG. 1A, the target gene sequence isdissected into number of overlapping oligonucleotides. The 3′ and 5′ arethe ends of the shown strand. FIG. 1A also shows, relative to the targetsequence, primer Pr1; extension product of primer Pr1, which iscomplementary to oligonucleotide 1; and extension product ofcomplementary oligonucleotide 1, which is complementary tooligonucleotides 1+2. FIG. 1B illustrates one embodiment of the initialsteps of an assembly process. In step 1 of assembly, Primer Pr1 isannealed to oligonucleotide 1 and extended by appropriate polymeraseenzyme into product complementary to oligonucleotide 1. The second stepis melting, re-annealing and extension (i.e., amplification) to lead toproduction of larger amount of Pr1 extension product (complementaryoligonucleotide 1), re-association of the complementary oligonucleotide1 with oligonucleotide 1, and to annealing of the complementaryoligonucleotide 1 with oligonucleotide 2 followed by its extension intoproduct complementary to oligonucleotides 1+2. FIG. 1C shows acontinuation of the assembly process from FIG. 1B. Specifically, step 3of the process (i.e., melting, re-annealing and extension) leads to thesame products as step 2 plus a product complementary to oligonucleotides1+2+3. Cycles (steps) are repeated until a full-length complementarypolynucleotide is formed. The final step is preparation of the finaltarget polynucleotide molecule in desirable amounts by amplification(i.e., PCR) using two primers complementary to the ends of this molecule(PrX and PrY).

FIG. 2 shows a second embodiment of the inventive gene assembly processusing oligonucleotides synthesized in situ onto a microarray device,each having a flanking sequence region containing a restriction enzymecleavage site, followed by a PCR amplification step and followed by aREII restriction enzyme cleavage step.

FIGS. 3A-3C show schematics for gene assembly using oligos synthesizedand then cleaved from a microarray device. Specifically, in FIG. 3A,oligonucleotide sequences are connected to the microarray device througha cleavable linker (CL) moiety. An example of a cleavable linker moietyis provided in FIG. 3A. The cleavable linkers are molecules that canwithstand the oligonucleotide synthesis process (i.e., phosphoramiditechemistry) and then can be cleaved to release oligonucleotide fragments.Chemical cleavage at cleavable linker CL recreates usual 3′ end ofspecific oligos 1 through N. These oligonucleotides are released into amixture. The mixture of oligonucleotides is subsequently assembled intofull-length polynucleotide molecules. FIG. 3B, oligonucleotide sequencesare connected to the microarray device through additional flankingsequence containing a restriction enzyme (RE) sequence site. Anotheroligonucleotide sequence, complementary to the flanking sequence region,is hybridized to the oligonucleotides on the microarray device. Thisrecreates a “ds” or double-stranded oligonucleotide structure, eachhaving a RE sequence recognition region in the flanking sequence region.Digestion of this ds oligonucleotides with the corresponding RE enzymesat the RE recognition sites in the flanking sequence regions releasesthe specific oligonucleotides 1 through N. When assembled,oligonucleotide sequences 1 through N form a full-length polynucleotidemolecule. FIG. 3C: Cleavable linker for oligonucleotide synthesis.

FIG. 4 shows the assembly of a polynucleotide from three oligonucleotidefragments wherein each oligonucleotide fragment was synthesized in situon a microarray device. The fully assembled polynucleotide was 172 mersin length, a length not practically achievable by in situ synthesis. Thefirst embodiment inventive process was used in this example.

FIG. 5 shows the oligonucleotide sequences (SEQ ID NO: 1, SEQ ID NO: 2,SEQ ID NO: 3) used to assemble the 172-mer polynucleotide (SEQ ID NO: 4)of FIG. 4. The sequences of primers X and Z are underlined. The Hpa IIrestriction site is indicated by italic underlined letters.

FIG. 6 shows a scheme for preparing the sequences of flanking regions(SEQ ID NO: 52 and SEQ ID NO: 53) and primers used for preparation ofspecific oligonucleotide for assembly using the REII enzyme MlyI. Primer1 is complementary to the oligonucleotide strand on a microarray deviceand contains a Biotin-TEG (triethylene glycol) moiety. Primer 2 is thesame strand as the oligonucleotide strand on microarray device andcontains Biotin-TEG moiety. Any sequence between the primers can be usedand is just designated by a string of N's.

FIG. 7 shows the results of PCR and Mly I digestion of anoligonucleotide sequence as described in FIG. 6. The clean bands showthe ability to obtain pure oligonucleotides using the second embodimentof the inventive process to cleave off oligonucleotide sequences usingappropriate restriction enzymes.

FIG. 8 shows the sequences from nine oligonucleotides fragments(consecutively numbered 1-9 and having SEQ ID NO: 5, SEQ ID NO: 6, SEQID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQID NO: 12, and SEQ ID NO: 13, respectively) used to assemble a 290 bppolynucleotide. The flanking regions are shown in bold and underlined.The process used for polynucleotide assembly was the second embodiment.The overlapping regions further contained a cleavable site as the Mly Irecognition site for the Mly I class II restriction endonuclease.

FIG. 9 shows a schematic in the top panel for assembling apolynucleotide from nine oligonucleotides. Nine oligonucleotidesequences, shown in FIG. 8, were amplified by PCR using primers 1 and 2(as described in FIG. 6) into ds DNA fragments containing the sameflanking regions and specific overlapping sequences, digested with Mly Ienzyme to remove flanking sequences, and used for assembly of 290 bp DNAfragment. The columns in the gel shown are M—markers, 1—negativecontrol, assembly without primers FP1 and FP2, 2—negative control,assembly without specific oligos, 3—assembly of 290 bp fragment fromspecific oligos plus amplification with FP1 and FP2 primers. The band incolumn 3 shows a high efficiency of the inventive polynucleotideassembly process.

FIG. 10 shows a sequence of an assembled polynucleotide in Example 4,broken down into its component oligonucleotides (Fragment 1, SEQ ID NO:14, Fragment 2, SEQ ID NO: 15, Fragment 3, SEQ ID NO: 16, Fragment 4,SEQ ID NO: 17, Fragment 5, SEQ ID NO: 18, Fragment 6, SEQ ID NO: 19,Fragment 7, SEQ ID NO: 20, Fragment 8, SEQ ID NO: 21, Fragment 9, SEQ IDNO: 22, Fragment 1F, SEQ ID NO: 23, Fragment 2F, SEQ ID NO: 24, Fragment3F, SEQ ID NO: 25, Fragment 4F, SEQ ID NO: 26, Fragment 5F, SEQ ID NO:27, Fragment 6F, SEQ ID NO: 28, Fragment 7F, SEQ ID NO: 29, Fragment 8F,SEQ ID NO: 30, Fragment 9F, SEQ ID NO: 31, Fragment 10F, SEQ ID NO: 32,Fragment 11F, SEQ ID NO: 33, Fragment 12F, SEQ ID NO: 34, Fragment 13F,SEQ ID NO: 35, Fragment 14F, SEQ ID NO: 36, Fragment 15F, SEQ ID NO: 37,Fragment 16F, SEQ ID NO: 38, Fragment 17F, SEQ ID NO: 39, Fragment 18F,SEQ ID NO: 40, Fragment 19F, SEQ ID NO: 41, Fragment 20F, SEQ ID NO: 42,Fragment 21F, SEQ ID NO: 43, Fragment 22F, SEQ ID NO: 44, Fragment 23F,SEQ ID NO: 45, Fragment 24F, SEQ ID NO: 46, Fragment 25F, SEQ ID NO: 47,Fragment 26F, SEQ ID NO: 48, Fragment 27F, SEQ ID NO: 49, Fragment 28F,SEQ ID NO: 50, Fragment 29F, SEQ ID NO: 51).

DETAILED DESCRIPTION OF THE INVENTION

The present invention describes the preparation of a polynucleotidesequence (also called “gene”) using assembly of overlapping shorteroligonucleotides synthesized or spotted on microarray devices or onsolid surface bead devices. The shorter oligonucleotides includesequence regions having overlapping regions to assist in assembly intothe sequence of the desired polynucleotide. Overlapping regions refer tosequence regions at either a 3′ end or a 5′ end of a firstoligonucleotide sequence that is the same as part of the secondoligonucleotide and has the same direction (relative to 3′ to 5′ or 5′to 3′ direction), and will hybridize to the 5′ end or 3′ end of a secondoligonucleotide sequence or its complementary sequence (secondembodiment), and a second oligonucleotide sequence to a thirdoligonucleotide sequence, and so on. In order to design or develop amicroarray device or bead device to be used for polynucleotide assembly,the polynucleotide sequence is divided (or dissected) into a number ofoverlapping oligonucleotides segments, each with lengths preferably from20 to 1000 bases, and most preferably from 20 to 200 bases (FIG. 1A).The overlap between oligonucleotide segments is 5 or more bases,preferably 15-25 bases to that proper hybridization of first to second,second to third, third to fourth and so on occurs. Theseoligonucleotides (or oligos) are preferably synthesized on a microarraydevice using any available method (i.e., electrochemical in situsynthesis, photolithography in situ synthesis, ink-jet printing,spotting, etc.). The direction of synthesis relative to the microarraydevice surface or porous matrix covering a microarray device can be from3′ to 5′ or from 5′ to 3′. Preferably, in situ synthesis is done in the3′ to 5′ direction.

In the first embodiment the inventive gene/polynucleotide assemblyprocess uses oligonucleotides immobilized on a microarray device. Themicroarray device itself or a porous reaction layer with immobilizedoligonucleotides can be used for the inventive gene/polynucleotideassembly process.

With regard to FIG. 1B, the process comprises several repeated steps ofmelting, annealing and extension (FIG. 1B), which can be performed inany thermal cycler instrument. The cycling program is similar to theprograms used for PCR. At the first step of gene/polynucleotideassembly, primer Pr1 is added and anneals to oligonucleotide 1 on themicroarray device and then extends by appropriate polymerase enzyme intoproduct complementary to oligonucleotide 1 (called complementaryoligonucleotide 1). At the second step of the process the productcomplementary to oligonucleotide 1 is melted from oligonucleotide 1,primer Pr1 is annealed again to the oligonucleotide 1 as well as productcomplementary to oligonucleotide 1 is partially re-anneals tooligonucleotide 1 and partially anneals to oligonucleotide 2 due to anoverlapping sequence region between oligonucleotide 1 andoligonucleotide 2. Extension of Pr1 leads to production of an additionalamount of Pr1 extension product (complementary oligonucleotide 1). Theannealing of the complementary oligonucleotide 1 to oligonucleotide 2followed by its extension leads to product complementary tooligonucleotides 1+2 (called complementary oligonucleotides 1+2).Similarly, at step 3 of the process melting, re-annealing and extensionlead to the same products as at step 2 plus a product complementary tooligonucleotides 1+2+3. These cycles of melting, annealing and extensionare repeated until full-length polynucleotide is formed. The number ofcycles should be equal or more than the number of oligos on microarraydevice. After formation, the final target polynucleotide molecule isamplified by a PCR process with two primers complementary to the ends ofthis molecule to the desirable amounts.

In a second embodiment, a plurality of oligonucleotides that togethercomprise (with overlapping regions) the target polynucleotide sequenceare synthesized on a microarray device (or can be synthesized on beadsas a solid substrate), wherein each oligonucleotide sequence furthercomprises flanking short sequence regions, wherein each flankingsequence region comprises one or a plurality of sequence sites forrestriction endonuclease, preferably endonuclease class II (ERII)enzymes. Each oligonucleotide is amplified by PCR using appropriateoligonucleotide primers to the flanking sequence regions to form apreparation of a plurality of oligonucleotides. The preparation ofoligonucleotides is treated then with appropriate REII enzyme(s)(specific to the restriction sequences in the flanking sequence regions)to produce flanking fragments and overlapping oligonucleotides that,together comprise the desired polynucleotide sequence. Flankingfragments and PCR primers are removed from the mixture, if desired, bydifferent methods based on size or specific labeling of the PCR primers.The oligonucleotides resembling the desired target polynucleotide thenassembled into the final target polynucleotide molecule using repetitionof the primer extension method and PCR amplification of the finalmolecule.

Specifically, in the second embodiment, the assembly process initiallyuses oligonucleotides immobilized on a microarray device or beads, viaimmobilization techniques, such as spotting or ink-jet printing or bydirect in situ synthesis of the microarray device using varioustechniques, such as photolithography or electrochemical synthesis. Theoverlapping oligonucleotide sequences are designed having an overlappingregion and one or two flanking sequence regions comprising a restrictionclass II recognition site (FIG. 2A). The assembled oligonucleotidestogether comprise the target polynucleotide sequence.

The length of flanking sequences is at least the length of REIIrecognition site. The flanking sequences are designed to have minimalhomology to the specific oligonucleotide sequences regions on themicroarray device. The flanking sequences can be the same for eacholigonucleotide fragment, or be two or more different sequences. Forexample, a pair of appropriate primers, called Pr1 and Pr2, was designedto amplify each oligonucleotide on a microarray device (FIG. 2) by PCR.Each primer may contain a binding moiety, such as biotin, that does notaffect their ability to serve as primers. After PCR amplification theamplified ds copy of each oligonucleotide was present in the reactionmixture. This reaction mixture was treated with the appropriate REIIenzyme or enzymes specific for the restriction sites in the flankingsequence regions. The digestion sites for REII were designed, aftercleavage, to produce the desired specific oligonucleotide sequencefragments that, when assembled will form the target polynucleotidesequence. As a result of digestion a mixture of specific double stranded(ds) overlapping oligonucleotide sequence fragments resembling thestructure of desired target polynucleotide, and ds flanking sequenceswere formed. If desired, these flanking sequences and residual primersare removed from the mixture using specific absorption through specificmoieties introduced in the primers (such as, for example, by absorptionon avidin beads for biotin-labeled primers), or based on the sizedifference of the specific oligos and flanking sequences and primers.The mixture of specific oligonucleotide sequences resembling target genesequence is used to assemble the final target polynucleotide moleculeusing repeated cycles of melting, self-annealing and polymeraseextension followed by PCR amplification of the final targetpolynucleotide molecule with appropriate PCR primers designed toamplify. This final PCR amplification step is routinely done in the artand described in, for example, Mullis et al., Cold Spring Harb. Symp.Quant. Biol. 51 Pt 1:263-73, 1986; and Saiki et al., Science 239:487-91,1988. PCR amplification steps generally follow manufacturer'sinstructions. Briefly, A process for amplifying any target nucleic acidsequence contained in a nucleic acid or mixture thereof comprisestreating separate complementary strands of the nucleic acid with a molarexcess of two oligonucleotide primers and extending the primers with athermostable enzyme to form complementary primer extension productswhich act as templates for synthesizing the desired nucleic acidsequence. The amplified sequence can be readily detected. The steps ofthe reaction can be repeated as often as desired and involve temperaturecycling to effect hybridization, promotion of activity of the enzyme,and denaturation of the hybrids formed.

In another embodiment for the assembly step, oligonucleotide sequencesthat together comprise the target polynucleotide molecule are assembledusing a ligase chain reaction as described in Au et al., Biochem.Biophys. Res. Commun. 248:200-3, 1998. Briefly, short oligonucleotidesare joined through ligase chain reaction (LCR) in high stringencyconditions to make “unit fragments” (Fifty microliters of reactionmixture contained 2.2 mM of each oligo, 8 units Pfu DNA ligase(Stratagene La Jolla, Calif.) and reaction buffer provided with theenzyme. LCR was conducted as follows: 95° C. 1 min; 55° C. 1.5 min, 70°C. 1.5 min, 95° C. 30 sec for 15 cycles; 55° C. 2 min; 70° C. 2 min,which are then fused to form a full-length gene sequence by polymerasechain reaction.

In another embodiment the ds oligonucleotide sequences are assembledafter preparation by chain ligation cloning as described in Pachuk etal., Gene 243:19-25, 2000; and U.S. Pat. No. 6,143,527 (the disclosureof which is incorporated by reference herein). Briefly, chain reactioncloning allows ligation of double-stranded DNA molecules by DNA ligasesand bridging oligonucleotides. Double-stranded nucleic acid moleculesare denatured into single-stranded molecules. The ends of the moleculesare brought together by hybridization to a template. The templateensures that the two single-stranded nucleic acid molecules are alignedcorrectly. DNA ligase joins the two nucleic acid molecules into asingle, larger, composite nucleic acid molecule. The nucleic acidmolecules are subsequently denatured so that the composite moleculeformed by the ligated nucleic acid molecules and the template cease tohybridize to each. Each composite molecule then serves as a template fororienting unligated, single-stranded nucleic acid molecules. Afterseveral cycles, composite nucleic acid molecules are generated fromsmaller nucleic acid molecules. A number of applications are disclosedfor chain reaction cloning including site-specific ligation of DNAfragments generated by restriction enzyme digestion, DNAse digestion,chemical cleavage, enzymatic or chemical synthesis, and PCRamplification.

With regard to the second embodiment of the inventive process(illustrated in FIG. 2), a target polynucleotide gene sequence (eitherstrand) is divided into number of overlapping oligonucleotide sequencesby hand or with a software program, as shown in FIGS. 1A-1C. Theseoligonucleotide sequences, plus flanking sequences A and B (having oneor a plurality of restriction enzyme sites in the flanking regionsequence), are synthesized (in situ) on microarray device, or on a beadsolid surface using standard in situ synthesis techniques, or spotted(pre-synthesized) onto a microarray device using standardoligonucleotide synthesis procedures with standard spotting (e.g.,computer-aided or ink jet printing) techniques. The oligonucleotidesequences are amplified, preferably using a PCR process with a pair ofprimers (Pr1 and Pr2). The primers are optionally labeled with specificbinding moieties, such as biotin. The resulting amplified mixture ofdifferent amplified oligonucleotide sequences are double stranded (ds).The mixture of ds oligonucleotide sequences are treated with anappropriate restriction enzyme, such as an REII restriction enzyme(e.g., Mly I enzyme), to produce mixture of different double stranded(ds) overlapping oligonucleotide sequences that can be assembled intothe structure of the desired polynucleotide (gene) and ds flankingsequences. Optionally, the flanking sequences and residual primers areremoved from the ds oligonucleotide sequence mixture, preferably by aprocess of specific absorption using specific binding moietiesintroduced in the primers (e.g., biotin), or by a process of sizefractionation based on the size differences of the specificoligonucleotide sequences and flanking sequences. The mixture ofspecific oligonucleotide sequences is assembled, for example, by aprocess of repeated cycles of melting, self-annealing and polymeraseextension followed by PCR amplification of the final molecule withappropriate PCR primers designed to amplify this complete molecule(e.g., as described in Mullis et al., Cold Spring Harb. Symp. Quant.Biol. 51 Pt 1:263-73, 1986; and Saiki et al., Science 239:487-91, 1988).

In yet another embodiment of the inventive process (illustrated in FIGS.3A-3B), the oligonucleotide sequences comprising the targetpolynucleotide sequence are synthesized on a microarray device or beadsolid support, each oligonucleotide having a cleavable linker moietysynthesized within the sequence, such that after synthesis,oligonucleotides can be cleaved from the microarray device into asolution. Examples of appropriate cleavable linker moieties are shown inFIG. 3A. In addition to this method of cleavage, a sequence containingRE enzyme site can be synthesized at the ends of oligonucleotidesattached to the microarray device. These oligonucleotides on themicroarray device then hybridize with an oligonucleotide complementaryto this additional flanking sequence and treated with an RE enzymespecific for the RE enzyme site. This process releases oligonucleotidefragments resembling the structure of the target polynucleotide. Thisset of oligonucleotides then can be assembled into the finalpolynucleotide molecule using any one of the methods or combination ofthe methods of ligation, primer extension and PCR.

In a third embodiment of the inventive process, a plurality ofoligonucleotides that can be assembled into a full length polynucleotideare synthesized on a microarray device (or beads having a solid surface)having specific cleavable linker moieties (FIG. 3A) or capable of beingcleaved from the solid support of the microarray device or beads by achemical treatment. The net effect is to recreate the functional 3′ endsand 5′ ends of each specific oligonucleotide sequence. After treatmentto cleave them, the oligonucleotides (each having overlapping regions)are released into a mixture and used for full-length polynucleotide geneassembly using any of the gene assembly processes described herein.

Specifically, in the third embodiment and as illustrated in FIGS. 3A-3B,a target polynucleotide sequence is dissected into number of overlappingoligonucleotide sequences by a software program or on paper, but notnecessarily physically in a laboratory. These oligonucleotide sequencesare physically synthesized on a microarray device. In alternative A, theoligonucleotide sequences are connected to the microarray device throughcleavable linker moiety. Chemical cleavage under basic conditions (e.g.,through addition of ammonia), at cleavable linker CL recreates the usual3′ end of the specific oligonucleotide sequences 1 through N.Oligonucleotide sequences 1 through N are released into a mixture. Themixture of oligonucleotide sequences is used for polynucleotideassembly.

In alternative B, oligonucleotide sequences are connected to amicroarray device through additional flanking sequence regionscontaining a restriction enzyme (RE) sequence site. A secondoligonucleotide fragment, complementary to the flanking sequence, ishybridized to the oligonucleotides on the microarray device. Thisrecreates a ds structure at the flanking sequence region, including theRE recognition site. Digestion of this ds DNA structure with RE enzymespecific to the RE recognition site in the flanking sequence region willrelease specific oligonucleotides 1 through N into a mixture solution.The oligonucleotides 1 through N are able to assemble into apolynucleotide molecule in solution.

In another example of alternative B, oligonucleotides that togetherassemble into the polynucleotide are synthesized on a microarray device,each having a flanking sequence on the microarray side. The flankingsequence further comprises a restriction endonuclease (RE) recognitionsite (see FIG. 3B). Oligonucleotides complementary to the flankingsequence region are added and hybridized to the oligonucleotides onmicroarray device. After hybridization a RE (restriction enzyme specificto the RE sequence in the flanking region) is added to the microarraydevice. Specific oligonucleotide sequences are released from themicroarray device as a result of RE digestion into a mixture. Themixture of specific oligonucleotide sequences ARE assembled into thefull-length polynucleotide sequence.

EXAMPLE 1

This example illustrates assembly of 172-mer polynucleotide sequencefrom non-cleavable oligonucleotide sequences synthesized on a microarraydevice according to the first embodiment inventive process (FIGS. 4 and5). Three oligonucleotides (sequences shown in FIG. 5) were synthesizedin situ on a microarray device according to an electrochemical process(see U.S. Pat. No. 6,093,302, the disclosure of which is incorporated byreference herein). The oligonucleotide sequences synthesized wereamplified by a PCR reaction with primers X (complementary to the strandof oligo #1) and Z (same strand as Oligo #3) (FIG. 5). After 45 cyclesof PCR using a PCR kit with AmplyGold® enzyme (Applied Biosystems) acorrect DNA fragment of 172 bp was synthesized (FIG. 4). Its subsequentdigestion confirmed the specificity of this enzyme with Hpa II producingtwo fragments of 106 bp and 68 bp.

EXAMPLE 2

This example illustrates the second embodiment of the inventive processfor preparing oligonucleotides for assembly into full-lengthpolynucleotides by PCR and REII (restriction enzyme) digestion. A singleoligonucleotide sequence was synthesized on a microarray deviceaccording to the procedure in Example 1 (see FIGS. 2 and 6). Theoligonucleotide sequence further comprised 2 flanking sequences, eachhaving a recognition site for a Mly I restriction enzyme. Thismicroarray device was subject to a PCR (25 cycles) reaction with twoprimers (shown in FIG. 7) to produce an amplified PCR fragment mixture.The amplified PCR fragment obtained was digested by Mly I restrictionenzyme and purified by a PCR purification kit (Qiagen) to producespecific oligonucleotides ready for assembly (FIG. 7). Similarly, thisspecific oligonucleotide was purified from the flanking sequences byabsorption of the digestion mixture by Streptavidin-agarose (Sigma).

EXAMPLE 3

This example illustrates the assembly of a 290 bp polynucleotidesequence from 9 oligonucleotide sequences, each having flankingsequences containing a MlyI restriction site. Each of the nine differentoligonucleotide sequences was synthesized on a microarray device throughan in situ electrochemistry process as described in example 1 herein.

The microarray device containing the nine specific oligonucleotidesequences (with flanking sequences as shown in FIG. 8) was used for PCRamplification of each oligonucleotide sequence using two primers, Primer1 and 2, described in FIG. 6 to form a mixture of ds oligonucleotidesequences. The primers were complementary to the flanking sequences. Themixture of the amplified ds oligonucleotide sequences was digested byMly I enzyme. Specific ds oligonucleotide sequences were purified andthen assembled into the final 290 bp polynucleotide sequence in twosteps as described in FIG. 2 and shown schematically in FIG. 9. At thefirst step of assembly 20 cycles of melting-annealing-extension wereused. The final product was amplified using two primers FP1 and FP2(FIG. 9) in 25 cycles of PCR into a 290 bp polynucleotide DNA.

EXAMPLE 4

This example illustrates the creation of a cDNA polynucleotide sequencecapable of coding on expression for fusion protein MIP-GFP-FLAG(Macrophage Inflammation Protein—Green Fluorescence Protein—FLAGpeptide) using thirty-eight overlapping oligonucleotide sequences (FIG.10). The 38 oligonucleotides were synthesized on a microarray deviceusing an electrochemical in situ synthesis approach, as described inexample 1. Each oligonucleotide sequence contained a cleavable linkermoiety (see FIG. 3A) at their 3′ end. After simultaneous deprotectionand cleavage of these oligonucleotide sequences by concentrated ammonia,the mixture of oligonucleotide sequences was purified by gel-filtrationthrough the spin column. The purified oligonucleotide sequences wereassembled into a polynucleotide by a process shown schematically inFIGS. 3A-3B. The resulting DNA polynucleotide was 965 bp and containedboth a T7 RNA-polymerase promoter and a coding sequence for MIP-GFP-FLAGfusion protein. The polynucleotide assembled in this example was used ina standard transcription/translation reaction and produced theappropriate MIP-GFP-FLAG fusion protein. The translated protein waspurified from the reaction mixture using anti-FLAG resin (Sigma). Thefunctional protein possessed green fluorescence signal in appropriateblue light. Accordingly, this experiment demonstrated that the inventivegene assembly process provided the correct DNA sequence coding for thefunctional protein.

1. A process for creating a mixture of nucleic acid sequences,comprising: (a) providing a plurality of nucleic acid sequences attachedto a solid or porous surface, wherein each nucleic acid sequencecomprises a different fragment of a target polynucleotide sequence andhas an overlapping sequence with another nucleic acid sequence, whereinthe plurality of nucleic acid sequences together comprise the targetpolynucleotide sequence; (b) releasing the plurality of nucleic acidsequences into a solution; and (c) subjecting the released nucleic acidsequences to assembly conditions comprising one or more of ligation,primer extension and polymerase chain reaction.
 2. The process of claim1, wherein the solid or porous surface is a microarray device or beaddevice.
 3. The process of claim 1, further comprising amplifying eachnucleic acid sequence to form a plurality of double-stranded nucleicacid sequences using a primer complementary to a primer region of atleast one flanking sequence located at the 3′ end, the 5′ end, or the 3′end and the 5′ end of each fragment, wherein the at least one flankingsequence is from about 7 to about 50 bases and comprises the primerregion and a sequence segment having a restriction enzyme cleavablesite.
 4. The process of claim 3, wherein the at least one flankingsequence is from about 10 to about 20 bases in length.
 5. The process ofclaim 3, further comprising cleaving the primer region from thedouble-stranded nucleic acid sequences at the restriction enzymecleavable site, thereby releasing the plurality of nucleic acidsequences into solution.
 6. The process of claim 3, wherein therestriction enzyme cleavable site is a class II endonuclease restrictionsequence.
 7. The process of claim 6, wherein the class II endonucleaserestriction sequence is cleavable by a restriction endonuclease class IIenzyme selected from the group consisting of Mly I, BspM I, Bae I, BsaXI, Bsr I, Bmr I, Btr I, Bts I, Fok I, and combinations thereof.
 8. Theprocess of claim 5, wherein the at least one flanking sequence furthercomprises a binding moiety for purifying the cleaved nucleic acids. 9.The process of claim 8, further comprising labeling the at least oneflanking sequence during the amplifying step using primer labeled withthe binding moiety.
 10. The process of claim 9, wherein the bindingmoiety is biotin or fluorescein.
 11. A process for creating a mixture ofdouble-stranded fragments, comprising: (a) providing a plurality ofnucleic acid sequences bound on a solid or porous surface, wherein eachnucleic acid sequence comprises a fragment of a target polynucleotidesequence; (b) amplifying each nucleic acid sequence to form a pluralityof double-stranded nucleic acid sequences using a primer complementaryto a primer region of at least one flanking sequence located at the 3′end, the 5′ end, or the 3′ end and the 5′ end of each fragment, whereinthe at least one flanking sequence comprises the primer region and asequence segment having a restriction enzyme cleavable site; and (c)cleaving the primer region from the plurality of double-stranded nucleicacid sequences at the restriction enzyme cleavable sites, therebyproducing a plurality of double-stranded fragments that togethercomprise the target polynucleotide sequence.
 12. The process of claim11, wherein each double-stranded nucleic acid sequence has anoverlapping region corresponding to another double-stranded nucleic acidsequence.
 13. The process of claim 11, wherein the at least one flankingsequence for each nucleic acid sequence is the same.
 14. The process ofclaim 11, wherein the at least one flanking sequence is designed to haveminimal homology to the double-stranded nucleic acid sequences.
 15. Theprocess of claim 11, wherein restriction enzyme cleavable site is aclass II endonuclease restriction sequence.
 16. The process of claim 15,wherein the class II endonuclease restriction sequence is cleavable by arestriction endonuclease class II enzyme selected from the groupconsisting of Mly I, BspM I, Bae I, BsaX I, Bsr I, Bmr I, Btr I, Bts I,Fok I, and combinations thereof.
 17. The process of claim 11, furthercomprising purifying the double-stranded fragments by sizefractionation.
 18. A process for creating a mixture of double-strandedfragments, comprising: providing a plurality of nucleic acids sequences,wherein each nucleic acid sequence comprises a fragment of a targetpolynucleotide sequence and further comprises at least one flankingsequence at the 3′ end, the 5′ end, or the 3′ end and the 5′ end of eachfragment, wherein each flanking sequence comprises a primer region and asequence segment having a restriction enzyme cleavable site; amplifyingeach nucleic acid sequence using a primer complementary to the primerregion of the at least one flanking sequence to form a plurality ofdouble-stranded nucleic acid sequences; and cleaving the primer regionfrom the plurality of double-stranded nucleic acid sequences at therestriction enzyme cleavable sites, thereby producing a plurality ofdouble-stranded fragments that together comprise the targetpolynucleotide sequence.
 19. A process for creating a mixture ofdouble-stranded nucleic acid sequences, comprising: providing aplurality of nucleic acid sequences, wherein each nucleic acid sequencecomprises a fragment of a target polynucleotide sequence and at leastone flanking sequence at the 3′ end, the 5′ end, or at the 3′ end andthe 5′ end of each fragment, wherein the at least one flanking sequencecomprises a primer binding site, each primer binding site beingcomplementary to a primer permitting amplification of the plurality ofnucleic acid sequences; and subjecting the plurality of nucleic acidsequences to amplification to form double-stranded nucleic acidscomprising double-stranded fragments, the double-stranded fragmentstogether comprising the target polynucleotide sequence.
 20. The processof claim 19, wherein the at least one flanking sequence furthercomprises a sequence segment permitting removal of the primer bindingsite.
 21. The process of claim 20, wherein the sequence segmentpermitting removal of the primer binding site is a class II endonucleaserestriction sequence.
 22. The process of claim 20, wherein each nucleicacid sequence further comprises a cleavable linker moiety.
 23. Theprocess of claim 20, wherein the at least one flanking sequence isdesigned to have minimal homology to the nucleic acid sequences.
 24. Theprocess of claim 20, wherein each nucleic acid sequence has a sequenceregion that is the same as or complementary to a sequence region ofanother nucleic acid sequence.
 25. The process of claim 20, wherein theplurality of nucleic acid sequences are provided on a solid or poroussurface.